PMID- 33907117
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20230915
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 17
DP  - 2021 Apr 30
TI  - Apatinib combined with S-1 as second-line therapy in advanced gastric cancer.
PG  - e25630
LID - 10.1097/MD.0000000000025630 [doi]
LID - e25630
AB  - Advanced gastric cancer (AGC) patients are not tolerant to the toxicities of 
      traditional chemotherapy and its second-line therapeutic regimens are limited. 
      The aim of the present study is to evaluate the efficacy and safety of apatinib 
      combined with S-1 as the second-line therapy for AGC patients.Patients with AGC 
      were enrolled in this study. Patients received oral apatinib (250 mg to 500 mg 
      once daily) and S-1(40 mg/m2 twice daily) on days 1-14. Each cycle was 28 days 
      and one course of treatment consisted of 2 cycles. Clinical efficacy and adverse 
      events (AEs) were observed. Kaplan-Meier method was used for survival 
      analysis.From November 2015 to December 2017, 58 AGC patients who failed 
      first-line chemotherapy were enrolled and assessed retrospectively. According to 
      the Response Evaluation Criteria in Solid Tumors (RECIST) standard, all patients 
      were evaluable for response. None achieved CR, and 10 (17.2%) achieved PR (95% CI 
      7.2%-27.3%). SD was observed in 58.6% (34/58) of patients (95% CI 45.6%-71.7%) 
      and NR in 24.1% (14/58) of patients (95% CI 12.8%-35.5%). The objective response 
      rate (ORR) and the disease control rate (DCR) were 17.2% and 75.8% respectively. 
      The median progression-free survival (PFS) and median overall survival (OS) were 
      143.1 days (95% CI 121.7-164.5) and 211.6 days (95% CI 162.9-219.7) respectively. 
      The multivariate analysis showed that the ECOG PS was the independent factor of 
      PFS and OS for AGC patients (PFS: HR = 3.565, 95% CI: 2.25-5.65, P < .001; OS: 
      HR = 3.676, 95% CI: 2.29-5.89, P < .001). The main AEs were fatigue (72.4%), 
      hypertension (46.6%), and leukopenia (48.3%).Apatinib combined with S-1 showed 
      promising efficiency and was well tolerated as the second-line therapy for AGC 
      patients. ECOG PS was the independent factor of PFS and OS for AGC patients. AEs 
      were moderate and controllable, and leukopenia or hypertension was predictable 
      factors for the PFS and OS of AGC patients.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Qiu, Zhi-Yuan
AU  - Qiu ZY
AD  - Department of Oncology.
FAU - Qin, Rong
AU  - Qin R
AD  - Department of Oncology.
FAU - Tian, Guang-Yu
AU  - Tian GY
AD  - Department of Oncology, People's Hospital of Jiangdu, Yangzhou 225200, Jiangsu, 
      China.
FAU - Zhang, Zhao
AU  - Zhang Z
AD  - Department of Oncology.
FAU - Chen, Meifang
AU  - Chen M
AD  - Department of Oncology.
FAU - He, Han
AU  - He H
AD  - Department of Oncology.
FAU - Xi, Yan
AU  - Xi Y
AD  - Department of Geriatrics, The Affiliated People's Hospital of Jiangsu University, 
      Zhenjiang.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Oncology.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drug Combinations)
RN  - 0 (Pyridines)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5S371K6132 (apatinib)
RN  - 5VT6420TIG (Oxonic Acid)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Drug Combinations
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Oxonic Acid/*administration & dosage
MH  - Progression-Free Survival
MH  - Pyridines/*administration & dosage
MH  - Response Evaluation Criteria in Solid Tumors
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*drug therapy/mortality/pathology
MH  - Tegafur/*administration & dosage
MH  - Young Adult
PMC - PMC8084084
COIS- The authors declare no conflict of interest.
EDAT- 2021/04/29 06:00
MHDA- 2021/05/05 06:00
PMCR- 2021/04/30
CRDT- 2021/04/28 05:47
PHST- 2020/09/15 00:00 [received]
PHST- 2021/01/29 00:00 [accepted]
PHST- 2021/04/28 05:47 [entrez]
PHST- 2021/04/29 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
PHST- 2021/04/30 00:00 [pmc-release]
AID - 00005792-202104300-00032 [pii]
AID - MD-D-20-09193 [pii]
AID - 10.1097/MD.0000000000025630 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Apr 30;100(17):e25630. doi: 
      10.1097/MD.0000000000025630.